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  I 
Abstract 
Aberrant DNA hypermethylation at CpG islands is a well-established phenomenon involved 
in transcriptional silencing of tumor suppressor genes. CpG island hypomethylation-mediated 
reactivation of oncogenes is also documented in several cancer types.  
DNA methylation and histone modifications catalyzed by DNA methyltransferases 
(DNMTs), histone deacetylases (HDACs) and histone acetyltransferases (HATs), 
respectively, result in chromatin structure changes and altered gene regulation. Two 
categories of drugs, affecting histone acetylation and DNA methylation, are currently 
considered in epigenetic therapy of cancer. There is some evidence that synergistic effects of 
HDACi and DNMTi are achieved by their action on common targets, including DNA 
methyltransferase 1 (DNMT1). During the past decade, the human cytomegalovirus (HCMV) 
has been detected in several types of cancer including glioblastoma, the most lethal primary 
brain tumor with poor survival, and medulloblastoma, the most common malignant pediatric 
brain tumor. HCMV infection in glioblastoma is associated with poor outcome and antiviral 
treatment, was shown to restrict tumor growth and longer survival in these patients. 
The aim of this thesis was to investigate events that may play a role in initiation and 
progression of cancer through epigenetic alteration with a special focus on HCMV infections. 
The main idea behind this approach is that, if epigenetic alterations and HCMV infection are 
highly prevalent in cancer, patients might benefit from effects caused by epigenetic and 
antiviral therapy. 
In study I, changes in DNA methylation by the histone deacetylase inhibitor (HDACi), 
trichostatin A (TSA) was investigated in Hep3B cells. The effect of TSA on DNA 
methylation was studied at gene specific and global levels. Our results suggest that TSA 
causes genomic hypomethylation and leads to a decrease of nuclear DNMT1 protein levels 
by changing the DNA methyltransferases (DNMTs) mobility in the nucleus.  
In study II, the impact of human cytomegalovirus infection on the host cell DNA 
methylation machinery was investigated. The results showed an alteration in the host cell 
DNA methylation machinery by the re-localization of DNMTs from the nucleus to 
cytoplasm. The data also suggested that DNA methylation influences cellular susceptibility to 
HCMV infection. 
In study III, we explored the effect of HCMV infection on DNMT1 in medulloblastoma 
(MB) cells and tumor biopsies as well as human endothelial cells since blood vessels within 
MB tumors have shown to most often express HCMV proteins, and are important for 
tumorigenesis. The data demonstrated cytoplasmic localization of DNMT1 in HCMV 
infected MB and endothelial cells associated with expression of HCMV late gene UL55 
(glycoprotein B, gB). Treatment of HCMV infected MB cells by the DNA methylation 
inhibitor, 5-azacytidine (5AZA), showed significant increased number of cells expressing 
viral protein. These data suggest that HCMV replication may benefit from inhibition of the 
host cell nuclear methylation machinery, a fact that may have consequences for using 
epigenetic drugs in cancer therapy. 
In Study IV (Manuscript), the expression and localization of DNA methyltransferase 1 
(DNMT1) and various HCMV proteins were assessed in glioblastoma (GBM) cells and 
patient tissue specimens. Moreover, the effect by 5AZA was analysed in the context of viral 
replication, proliferation and invasion ability of HCMV infected GBM cells.  
Our data show that DNMT1 is localized to the extra-nuclear space of GBM cells expressing 
HCMV-gB proteins and in the cells of blood vessel wall within GBM tumors. 
In tissue specimens, DNMT1 was shown to be expressed in the nucleus of tumor cells, but 
localized to the extra-nuclear /cytoplasmic space of cells lining blood vessel walls within the 
GBM tumors. 5AZA treatment of GBM cells lead to reduced proliferation of uninfected and 
HCMV infected cells and HCMV infected cells were shown to be vulnerable to 5AZA 
treatment, leading to a decreased invasion. 
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  1 
1 INTRODUCTION 
When I started this journey, the association between human cytomegalovirus (HCMV) and 
malignant gliomas (GBM), an incurable and aggressive primary brain tumor in adults, was 
shown by Cobbs et al. [1]. Later, between 2002 and 2012, several studies showed the 
presence of HCMV in other malignant tumors, such as colon cancer [2], breast cancer [3], 
prostatic carcinoma [4], mucoepidermoid carcinoma and salivary gland [5], as well as 
rhabdomyosarcomas [6]. Furthermore, Cecilia Söderberg-Nauclér’s research group found 
longer survival in GBM patients, whose tumors had a low grade of HCMV infection in 
comparison to high grade, and the patients who received anti-viral treatment, valganciclovir, 
in addition to standard therapy. These data later got published in 2013 and 2015, respectively 
[7] and [8]. The standard treatment for GBM patients includes maximal surgical resection, 
followed by radiotherapy plus concomitant and maintenance temozolomide (TMZ) 
chemotherapy [9]. The TMZ is a DNA alkylating drug which results in methylation of 
guanine residues, inducing DNA damage and causing death of tumor cells [10].  
Epigenetics is the principle of additional layers of genomic information for regulation of the 
primary DNA sequence, and include DNA methylation, and in its broader definition, histone 
modification, micro RNA, and chromatin remodeling. DNA methylation is heritable through 
cell divisions, reversible and dynamic, and is involved in a variety of diseases such as cancer 
[11-14], neurological disease [15] and viral latency and reactivation [16]. In the past decade, 
DNA methyltransferase inhibitors (DNMT inhibitors) and histone deacetylase inhibitors 
(HDAC inhibitors) have been recognized as potential antitumor drugs [17-19]. 
The epigenetic therapy that targets key proteins, like DNMTs and HDACs, has been 
clinically exploited in cancer treatment [20, 21]. In contrast to genetic errors in cancer, 
epigenetic aberrations can be modulated by chemical agents, and this makes them promising 
targets in cancer therapy. Among the identified epigenetic regulations in cancer, DNA 
methylation has been broadly investigated [22]. Due to this information, we started a project 
to study effects of epigenetic changes, specifically DNA methylation, associated to HCMV 
infection in CNS tumors. The method to study global genomic DNA methylation (LUMA), 
using a luminometric technology to quantitate methylation sensitive restriction digestions 
[23] had already been stablished in our lab when I started my project. 
Below, I am describing my journey, my publications, and how this study may be of help in 
cancer treatment, and finally I mention all the people who were important in this journey. 
1.1 EPGENETICS 
To package and fit the entire length of around 2 meters of eukaryotic DNA in the nucleus of 
the mammalian cell, DNA is coiled around histone proteins building nucleosomes, and 
organized in a structure called chromatin. [24, 25]. Nucleosomes are the repeating units of 
chromatin consisting of histone octamers, on which 145-147 base pairs of DNA are wrapped. 
A histone octamer consists of two copies each of H2A, H2B, H3 and H4 which is compacting 
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DNA five- to ten-fold. This assembly of DNA and histone proteins are connected to the 
neighboring nucleosome by short DNA segments (∼10–80 bp in length) called linker DNA 
and form chromatin fibers, with a diameter of ∼10 nm, known as beads on a string [26, 27]. 
These fibers are then stabilized by binding of a fifth histone, H1, to each nucleosome and its 
adjacent linker, known as the 30 nm fibers. The condensation of these can be seen in the 
cell’s metaphase and is defined as chromosomes. This structure is highly dynamic such that it 
has the potential to switch between a compact and accessible form of chromatin. 
The compact form of the chromatin is inaccessible (heterochromatin) and therefore provide a 
poor template for biochemical reactions such as transcription, whereas the accessible form of 
chromatin, (euchromatin) is associated to active genes. This chromatin flexibility is 
associated to a wide range of histone modifications that are correlated with gene activity, 
DNA replication and DNA repair [27]. 
More than 100 different cell types in the human body have different fate and phenotype even 
though all of them carry identical genetic information and are derived from a single cell. The 
regulatory mechanisms that guide the cell to follow different developmental pathways and 
differentiate into different cells involve epigenetics [28]. In other words, epigenetics is “the 
study of heritable and potentially reversible properties in genome function, which are not 
directly dependent on the primary sequence of DNA”. This means that some of the associated 
information with DNA, which is not embedded in the primary sequence, can also be inherited 
through cell division and transferred to daughter cells. During this process, the memory of a 
mother cells’ function and phenotype can be retained in daughter cells [29]. Epigenetics is a 
very important level for interpretation and directing the function of the genome. Alterations 
of epigenetic states result in effects on DNA-protein interactions, in chromatin structure and 
compaction, and may also lead to significant alterations in gene expression [30] [31]. These 
epigenetic mechanisms ultimately play critical roles in various life process such as cell 
differentiation, growth, development, aging and immune response. Due to these functions, 
epigenetics can explain how environmental factors contribute to our individual phenotypes 
and explain susceptibility to certain disease such as cancer. In addition, epigenetic 
modifications can be considered as biomarkers for therapeutic treatments [32]. 
Epigenetic modifications are primarily comprised of DNA methylation, histone modification, 
micro RNA (miRNA)-mediated and long non-coding RNA (lncRNA)-mediated regulation 
[33]. One should be aware however, that only DNA methylation lives up to the original strict 
definition of epigenetic modification, i.e. heritability over cell divisions [34]. As the studies in 
this thesis have been focused on DNA methylation and histone modification, these are 
discussed in more detail in the following sections. 
  3 
 
Fig 1. Chromatin structure, including histones and DNA, Adapted from 
(https://www.whatisepigenetics.com/fundamentals) 
 
1.1.1 Histone modifications 
Histones are nuclear proteins that perform critical functions in packaging and organizing 
DNA into structural units and to maintain gene regulation. According to the “histone code” 
hypothesis, the location and combination of histone tail marks has significance for eliciting 
downstream effects on cellular functions such as DNA replication, DNA repair, and mitosis, 
condensation, maintenance of centromeres and telomeres, and gene expression [35, 36]. 
Modification of chromatin can be divided into the adenosine triphosphate (ATP)-dependent 
chromatin-remodeling complexes, incorporation of histone variants and covalent histone 
modifications [37, 38]. Chromatin remodeling enzymes cooperates with site specific 
transcription factors and histone modification enzymes to move or to eject histones to be 
available for transcription factors to DNA [39]. Another mechanism which affect chromatin 
structure is incorporation of histone variants, of mainly H2A and H3. For example H2A can 
be replaced by H2AX (which is associated with DNA repair) and H3 can be replaced by H3.3 
(associated with gene activation) or CENPA (associated with the centromer) [27]. The 
structure and function of chromatin are also controlled by covalent modification of histones. 
The subunit of histones (H2A, H2B, H3, and H4) contain N-terminal tails which are 
accessible to enzymes for chemical modifications which in turn affect the histone DNA 
interaction and modulate chromatin structure. Several different types of histone modifications 
are known, including acetylation, mono-, di-, or tri-methylation, phosphorylation, 
ubiquitination [35] [36, 40]. The combination of these modifications can produce millions of 
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different possibilities for each nucleosome. These enormous combinations can be read out by 
regulatory proteins and affect e.g. gene expression [41]. 
1.1.1.1 Histone Acetylation  
Acetylation states of histones is the most studied histone posttranslational modification in the 
epigenome and it is associated with chromatin structure affecting gene activity [42]. Histone 
acetyltransferases (HATs) and histone deacetylases (HDACs) represent two enzyme classes 
that, respectively, catalyze the forward and backward reaction kinetics of lysine residue 
acetylation on specific protein substrates [43]. HATs catalyze acetylation by transferring of 
an acetyl group from acetyl-CoA to lysine residues in the histone tail. Thus, histone 
acetylation facilitates DNA accessibility and the interaction between DNA and other proteins 
including transcription factors, by reducing the attractive positive charge of histones to the 
negatively charged DNA backbone. HDACs, on the other hand, remove acetyl groups from 
histone tails leading to a greater attraction between the DNA backbone and the lysine positive 
charge, and package the chromatin into a more condensed structure. This prevents the 
accessibility to transcription factors and consequently inhibits transcription [43, 44]. To date, 
18 human HDACs have been identified which are classified into four classes due to their 
localization in the nucleus or cytoplasm. HDAC1, 2 and 3 which are mainly located in the 
cell nucleus [45-47]. 
Regarding the involvement of the HAT-HDAC system in turnover of histone and 
transcription machinery regulation, the function of these two enzyme is one of the basic 
regulatory switches of gene expression. In addition to transcription regulation by HATs-
HDACs, they are also postulated to modulate other chromatin-associated processes like 
replication, site-specific recombination and DNA repair, thereby playing a major role in 
modulating overall cellular fate [43]. A controlled balance between histone acetylation and 
deacetylation appears to be essential for normal cell growth [48]. Alterations in the structure 
or expression of HATs and HDACs has been reported in different cancers [49-52]. In most 
tumor cells, chromatin is hypoacetylated due to disruption of HATs activity or 
overexpression of HDACs. The hypoacetylation status of chromatin has been associated with 
low expression of either tumor suppressor genes or pro-apoptotic genes [53, 54]. It should be 
mentioned that both HATs and HDACs are not only modifying histone proteins, although 
their names suggest this. Many cellular proteins, e.g. the tumor suppressor protein p53 
latency, are regulated by these enzymes [55]. The overexpression of HDACs, appears to 
silence tumor suppressor genes such as p21, a cell cycle progression inhibitor, resulting to 
tumor initiation and/or progression. It has been reported that the acetylation state of p53 by 
HATs/HDACs is part of the mechanisms that control the physiological activity/latency of p53 
[55] 
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1.1.1.2 Histone deacetylase inhibitor 
Perturbation of the balance between HDACs and HATs enzymes is, as mentioned above, 
often observed in human cancers, and inhibition of HDACs has developed as a new 
therapeutic strategy against cancer [56]. HDAC inhibitors are chemical agents inhibiting the 
activities of HDAC enzymes, causing an increase in the level of acetylated histones. This 
hyperacetylation in turn can promote the re-expression of silenced regulatory genes and may 
reverse the phenotype of cancer cells [57]. Pharmaceutical evaluations have shown that these 
drugs are able to selectively inducing growth arrest and apoptosis in different tumor cells 
while they have low toxicity in normal cells [57-59].  
There are four main classes of HDAC inhibitors based on their distinct chemical structure, 
comprising hydroxamates (e.g. suberoylanilide hydroxamic acid (SAHA)), and hydroxamic 
acids, such as Trichostatin A (TSA), benzamides (e.g. MS-275), cyclic peptides (e.g. 
Romidepsin (FK-228)) and aliphatic acids (e.g. Valproic acid) [60]. The approval of three 
HDACIs (SAHA, FK-228 and recently PXD-101) by the Food and Drug Administration 
(FDA) has been followed by the development of more efficient and more potent HDACIs in 
cancer therapy [61, 62]. 
- Trichostatin A (TSA) 
TSA is an antifungal antibiotic with cytostatic and differentiating properties in mammalian 
cell culture. As a HDAC inhibitor, its effect can be paramount by e.g. arrest the cell cycle and 
induce cell differentiation in culture [63, 64]. It has been reported that TSA is a potent 
inhibitor of tumor growth of human breast cancer cells [63]. Trichostatin A (TSA), has also 
been shown to reactivate DNA methylation-silenced genes even in the absence of DNMT 
inhibitors, suggesting a cross-talk between histone acetylation and DNA methylation [65]. In 
addition, it has been reported that TSA decreases DNMT3b mRNA levels in endometrial cell 
lines [66] and DNMT1 levels in Jurkat T cells [67]. 
- SAHA (Vorinostat) 
SAHA has a similar structure as TSA and treatment of cells in culture with SAHA results in a 
marked hyperacetylation of histone H4 [68]. SAHA is used for the treatment of cutaneous T-
cell lymphoma [69]. FK-228 (Romidepsin) is a cyclic peptide HDAC inhibitor, which 
acquired FDA approval for the treatment of cutaneous T-cell lymphoma and peripheral T-cell 
lymphoma [70]. 
Concerning gliomas, HDAC inhibitors such as TSA and Valproic acid (VPA) promote 
growth inhibition and apoptosis in different glioma cell lines [71]. VPA and other HDAC 
inhibitor drugs were examined in clinical trials and may be preferred among other drugs for 
prophylaxis and treatment of seizures in GBM patients [72, 73]. VPA has also been used for 
treatment of epilepsy and bipolar disorder [74].VPA causes hyperacetylation of the N-
terminal tails of H3 and H4 in vitro and in vivo and inhibits HDAC activity, probably by 
binding to the catalytic center and blocking the access of the substrate [75].This drug 
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influences differentiation and has antiproliferative effects by inducing the cyclin-dependent 
kinase inhibitor p21; p21 regulates cell-cycle progression (WAF1) [76]. 
1.1.2 DNA methylation 
In 1948, Rollin Hotchkiss discovered modified cytosine in calf thymus using paper 
chromatography. He hypothesized that this modified cytosine was 5-methylcytosine (5mC) 
and naturally existed in DNA [77]. In 1978, it was reported that DNA methylation occurred 
almost exclusively on cytosine in a CpG dinucleotide context [78]. In the 1980s, several 
studies showed that DNA methylation was involved in gene regulation and cell 
differentiation [79, 80]. After these findings, several studies extensively showed the 
association between DNA methylation changes, in different diseases and carcinogenesis [81-
86].  
Many genomes contain various amounts of methylated bases, such as C5-methylcytosine 
(5mC), N4-methylcytosine (4mC) and N6-methyladenine (6mA) [87]. The main methylation 
in the eukaryotic genome is represented by 5mC [88, 89] and occurs on the 5 position of 
cytosine [90] [31]. Approximately 60% of gene promoters contain CpG islands (CGIs) and 
are largely unmethylated. CGIs are regions of more than 200 bases with a C+G content of at 
least 50% [91]. Some promoter-associated CGIs (approximately 6%) become methylated in a 
tissue-specific manner during early development or in differentiated tissues and result in 
silencing of downstream genes [91, 92]. 
In the human genome, containing approx. 56 million CpG sites, about 60-80% are methylated 
which is almost 4-6% of all cytosines [93]. These methylated CpGs are not randomly 
distributed but follow tissue and cell specific patterns [94, 95]. 
The process of establishment and maintenance of cytosine methylation is catalyzed by DNA 
methyltransferases (DNMTs) in the presence of the S-adenosylmethionine (AdoMet or SAM) 
cofactor as methyl group donor [96]. The human genome encodes five DNMTs; DNMT1, 
DNMT2, DNMT3a, DNMT3b and DNMT3L.  DNMT1, DNMT3a and 3b are canonical 
methyltransferases that catalyze the addition of methyl group from SAM as a methyl donor to 
the cytosine within (usually) CpG dinucleotide of genomic DNA. DNMT2 and DNMT3L, in 
contrast, are non-canonical family members and DNMT3L has no catalytic activity [97]. 
DNMT1 prefers hemimethylated DNA over unmethylated DNA, and thus copy the existing 
methylation pattern of DNA during replication, which results in maintenance of the DNA 
methylation pattern through cell divisions [96, 98]. The DNMT3a and DNMT3b do not 
distinguish between unmethylated and hemimethylated DNA and mediate de novo 
methylation [99-101]. DNMT3L (DNMT-like protein) is catalytically inactive and does not 
have a functional catalytic domain [102]. 
Except for DNMT2, animal DNMT enzymes are usually multi domain proteins and contain 
two functional domain; an N-terminal regulatory domain and a conserved C-terminal domain 
required for catalysis. DNMT2 consists exclusively of the catalytic domain [103, 104]. 
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DNMT2 is a highly conserved methyltransferase that specifically methylate tRNA instead of 
genomic DNA [105, 106]. In mammals, the regulatory domain guides DNMTs localization to 
chromatin by interacting with other proteins and DNA and regulates their intrinsic activity. 
The catalytic domain includes six different motifs involved in DNA binding and catalysis of 
methyl group transfer [102]. 
 
 
Fig 2. Schematic structure of mammalian DNMT family members, The N-terminal 
contains motifs of interaction with proteins or DNA. The C-terminal contains the 
conserved methyltransferases domains. PHD, plant homology domain, adapted from 
Dharmalingam Subramaniam et al. 2014 
 
1.1.2.1 DNA methylation in different disease 
DNA methylation has been shown to associate with many human diseases, including 
different types of cancer [107, 108], autoimmune diseases such as systemic lupus 
erythematosus [109], neurological disorders such as Alzheimer’s and Parkinson’s diseases 
[110] and psychological disorders. Also, it has been suggested that methylation can be 
involved in multifactorial diseases such as multiple sclerosis, cardiovascular disease and 
disease influenced by secondary factors such as sex differences and aging [111, 112]. 
Microarray studies in monozygotic twins and subsequently in unrelated individuals, 
confirmed a global decrease in DNA methylation with age, while site specific analysis 
showed an increase in variability of DNA methylation with age [113-115]. Emerging 
evidence has already shown the association between DNA methylation and inflammation in 
regulating immune pathways. For example, elevation of the cytokine IL-6 increases the 
expression of DNMT1 in T cells [116-119].  DNA methylation is involved in regulating 
differentiation, migration, and activation of T-cells [117, 118]. Another example is the 
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demethylation of the IL-2 promoter which results in upregulation of IL-2 and activation of T-
cells [120]. 
SAM is thought to play an important role in brain development, reflecting its dominant and 
ubiquitous effects on cell biology in epigenetic psychiatry [121]. 
Three noticeable enzymes which catalyze DNA demethylation, are the Ten-Eleven 
Translocation enzymes (TETs), Tet1, Tet2, and Tet3 [122]. TET1, the most highly expressed 
TET in brain, is essential for the learning dependent accumulation of 5- 
hydroxymethylcytosine (5-hmC) and related, which underpins rapid behavioral adaptations 
based on epigenetic activation. TET1 has a role in neuronal activity-induced, region-specific, 
active DNA demethylation with concomitant gene expression changes [123]. In addition to 
catalytic activity, TET1 controls the levels of DNA methylation and thus regulates memory 
formation [124].  
MECP2 encodes a methyl-DNA-binding protein that has been proposed to function as a 
transcriptional suppressor. MECP2 is a member of the MBD (methyl-CpG binding domain) 
proteins, is the highest expressed nuclear protein in the brain and known as a reader of DNA 
methylation. MECP2 binds to methylated DNA and mediates the molecular consequences of 
this epigenetic mark by recruiting other proteins involved in repression [125, 126].  
Several studies showed that MECP2 is important for synapse maturation. The mechanism of 
MECP2 as a transcriptional repressor is not clear, although one study showed that it represses 
gene expression by binding to methylated CA dinucleotide sites within long genes [127-131]. 
Rett syndrome (RTT), a severe neurological disorder with feature of autism, is the result of 
disruption in the MECP2 gene [132] 
1.1.2.2 DNA methylation in cancer 
Cancer has traditionally been defined as a disease that originate from the accumulation of 
genetic mutations [133]. However, this definition has now been expanded to disruption of 
epigenetic regulatory mechanisms, which are prevalent in cancer [134, 135]. Both genetic 
mutations and epigenetic alterations ultimately involve abnormal gene expression. The 
genetic pathways of cancer include mutation of tumor suppressor and/or oncogenes which 
causes either gain or loss of gene function and/or abnormal gene expression. The epigenetic 
path of cancer involves chromatin structure, including DNA methylation, histone variants and 
modifications, nucleosome remodeling and small non-coding RNAs [136]. During tumor 
initiation and progression, the epigenome goes through multiple alterations, such as genome-
wide loss of DNA methylation (hypomethylation), frequent increases in promoter 
methylation of CpG islands in tumor suppressor genes, changes in nucleosome occupancy 
and modification profiles. Thus, genetic and epigenetic alteration is now thought of as two 
separate mechanisms in tumorigenesis but whole exome sequencing of thousands of human 
cancers showed that these two mechanism are not separated events and they intertwine and 
take advantage of each other during carcinogenesis. Interestingly genetic mutations have the 
potential to disrupt the pattern of DNA methylation, histone modifications and nucleosome 
positioning. The other side of the coin is that epigenetic alteration can lead to mutations in 
  9 
key genes and changing of gene expression [137], e.g. the methyl guanine methyl transferase 
gene (MGMT) whose gene product removes carcinogen-induced O6-methylguanine adducts 
from DNA and results in transition from G to A, can be hypermethylated in cancer. 
Hypermethylated MGMT may results in genetic mutation in critical genes such as p53 or 
KRAS [138, 139]. DNA methylation was the first epigenetic alteration identified in cancer 
[86]. Global DNA hypomethylation plays a major role in carcinogenesis and can occur at 
different genomic loci such as repetitive sequences, retrotransposons, CpG promoters, introns 
and gene desert; regions of the genome that are devoid of protein-coding genes [140]. DNA 
hypomethylation can induce genomic instability which is implicated in a variety of human 
cancer [141, 142] and activate proto-oncogenes [143]. In addition, hypomethylation of DNA 
can lead to the activation of growth-promoting genes, such as R-Ras and MAPSIN in gastric 
cancer, S-100 in colon cancer and MAGE (melanoma-associated antigen) in melanoma, and 
loss of imprinting (LOI) resulting in pediatric tumors associated with Beckwith-Wiedeman 
Syndrome (hepatoblastoma, Wilms tumor etc.) [144, 145].  
Site specific DNA promoter hypermethylation is involved in carcinogenesis by silencing of 
tumor suppressor genes [81]. Promoter hypermethylation induce silencing of RUNX3 
transcription factors in esophageal cancer, GATA-4 and GATA-5 transcription factors in 
colorectal and gastric cancers, leads to inactivation of their downstream target [146, 147]. 
Inactivation of DNA repair genes which enables cells to accumulate genetic lesions can lead 
to progression of cancer [148]. In addition to direct inactivation of tumor suppressor genes, 
DNA hypermethylation can also indirectly affect transcription factors and DNA repair genes. 
In support of developmental selectivity, DNMT1 and DNMT3a are expressed in both adult 
and the embryonic stages of the brain, whereas DNMT3b is just detectable during early 
neurogenesis [149]. There is a transition of mouse de novo methyltransferase expression from 
Dnmt3b to Dnmt3a during neural progenitor cell development [150] suggesting DNMTs as 
playing a particular role in neural function at specific times over neural maturation and 
development [151]. 
1.1.2.3 DNA methylation inhibitors 
Aberrant DNA methylation in cancer and other diseases on the one hand and the reversible 
nature of epigenetic aberrations on the other hand, have led to making DNA methylation 
inhibitors as attractive targets for therapeutic intervention [136, 152].  
Only two DNA methylation inhibitors have been FDA approved for cancer treatment. The 
cytosine analogs 5-azacytidine (5AZA, Vidaza®) and 5-aza-2'-deoxycytidine (decitabine, 
Dacogen®)) are demethylating agents successfully employed for myelodysplastic syndromes, 
acute myeloid leukemia and chronic myelomonocytic leukemia. These inhibitors are 
incorporated into the DNA and covalently trap DNMTs, resulting in global hypomethylation 
of the genome [153-156]. This hypomethylation or demethylation, can effect gene expression 
by re-activating tumor suppressor genes resulting in cancer cell death [157]. 5AZA can also 
independently change gene transcription by incorporating to RNA and alter mRNA stability. 
Additionally, 5AZA and decitabine cause DNA damage and activate the DNA damage 
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response in some cells; however, the nature of this DNA damage has not been fully 
characterized and is likely cell type-dependent [158]. Although these drugs are known to 
demethylate DNA, the link between demethylation-induced transcription and the therapeutic 
effects of these drugs is not well established [156]. Due to high toxicity, low specificity, 
chemical instability and the poor bioavailability of these drugs during cancer therapy, 
development of a new generation of nucleoside drugs is ongoing [154, 159]. The prodrug 
SGI-110 derived from decitabine is under investigation in phase 2 clinical trials for the 
treatment of myelodysplastic syndromes and acute myeloid leukemia [160, 161]. In 
epigenetic therapy, the combination of the hypomethylation agent 5AZA and HDAC 
inhibitors has a synergistic therapeutic effect on solid tumor and abolished chemo resistance 
in cancer cells [162, 163]. 
1.2 HUMAN CYTOMEGALOVIRUS (HCMV) 
In 1898, nearly 120 years ago, Beijerinck, a Dutch microbiologist and botanist, was the first 
to suggest virus to be the incitant of the tobacco mosaic discoloration.  The word virus 
originates from a Latin word meaning "venomous substance”. 
The first human virus described was the agent, which causes yellow fever transmitted by 
mosquitoes, discovered and reported in 1901. The agent was studied because many soldiers 
died of yellow fever in the Spanish-American war in 1980. Since then, there are many 
historical examples of mortality caused by viruses that led to a wealth of subsequent research 
to understanding the viral role in different diseases. Now we know viruses as infectious 
obligatory intracellular parasites comprising genetic material surrounded by a protein coat 
and/or membrane that can infect living cells [164] [165, 166]. 
1.2.1 Discovery and history of HCMV 
In 1881, a German pathologist, Ribbert, observed enlarged cells in kidney specimen from 
stillborn infant who had died of syphilis like symptoms. He was unable to interpret this 
observation until he saw the report by Jesionek and Kiolemenoglou in 1904 [167]. 
Löwenstein described cytoplasmic and nuclear inclusions in these protozoal-like cells, 
followed by a clear halo in 1907 [168-170]. In the same year, Goodpasture and Talbot 
described these enlarged cells and used the term ‘cytomegalia’ although they did not have a 
clear explanation for the cause [171]. In 1925, Von Glahn and Pappenheimer shown that 
infected cells by herpesviruses contained inclusion bodies. They concluded that cytomegalic 
cells more likely were caused by a virus rather than protozoa [172]. Other researchers later 
supported the suggestion that a virus is the likely cause of the pathology of these cells, and 
this condition was termed a ‘generalised cytomegalic inclusion disease’ for the unknown viral 
aetiology of this pathology [173]. Minder later found the 199 nm particle in the clear halo 
around the intracellular inclusion of pancreatic cells in a case of cytomegalic inclusion 
disease by electron microscopy [174]. 
In the 1950, the virus was isolated from tissue cultures of human adenoid and salivary gland, 
and was called `salivary gland virus’ and thereafter, in 1960, Weller and colleagues proposed 
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the term `cytomegalovirus´ (CMV) [175, 176]. Propagation and isolation of CMV became 
possible once human cells were routinely grown in culture. Discovery of cell culture 
techniques enabled further development of the understanding of the nature of this virus, such 
as detection of virus protein, its life cycle and later its molecular pathogenesis [168, 177]. 
1.2.2 Epidemiology and transmission 
Human cytomegalovirus (HCMV) infects 45%-100% of the world′s population, 
approximately 60% of adults in developed countries, and 100% in developing countries due 
to socio-economic circumstances [178, 179]. HCMV can be transmitted through different 
routes including horizontal close personal contact, vertical transmission from mother to child, 
also through other bodily fluids via breast feeding, urine, blood transfusion, stem cell and 
organ transplantation, and sexual contact [179]. A primary infection can be acquired in a 
fetus, a neonate, a toddler, a child or an adult that is generally mild or asymptomatic in 
immunocompetent hosts [180-182]. Even though acute symptoms are rare in 
immunocompetent, healthy hosts can have symptoms including headache, fever, a sore 
throat, malaise, lethargy, splenomegaly, lymphadenopathy, upper respiratory tract infection 
or more severe mononucleosis [183]. In contrast to healthy people, HCMV can cause life-
threatening disease in immunocompromised patients. HCMV can induce distinct end-organ 
diseases in patients with HIV/AIDS, transplant recipients treated with immune suppressants, 
premature infants and individuals with a suppressed immune system [180, 184]. 
HCMV is the most important infectious agent associated with acute and chronic rejection in 
transplant patients, cardiovascular diseases [185], bacterial [186]and fungal infections [187], 
post-transplant diabetes [85, 188, 189] and significant morbidity and mortality following 
organ transplantation [190, 191] 
Recent meta-analysis reveal a significant connection between HCMV and increasing risk of 
atherosclerosis and vascular disease [192, 193]and it has been shown that HCMV infection is 
associated with an increased risk for inflammatory bowel disease (IBD) [194]and steroid-
resistant IBD [195]. During the last years, emerging evidence suggest that human 
malignancies arising from different tissues can be attributed to HCMV [1-4, 6, 196, 197]. 
1.2.3 Herpesviridae 
Herpesviriedae is a large family of viruses with linear double stranded DNA (100-225kbp), 
which can infect most vertebrates, from fish to mammals [198]. According to phylogeny 
analysis, the herpesviridae family emerged 180-220 million years ago, probably before 
generating the mammalian line, 80 to 60 million years ago [199] .  
Among hundreds of known herpesviruses, at least eight species can infect humans, and are 
classified into three subfamilies, alpha, beta and gamma, according to differences in their 
biological properties such as host cell tropism, latency and their different clinical 
manifestations [199]. Alpha herpesviridae includes, HSV1, HSV2 (Herpes Simplex virus 1, 
2) and VZV (Varicela Zoster Virus) and have a variable host range. HSV-1 and -2 and VZV 
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remain latent in neuronal cells of dorsal root ganglia [200, 201]. Approximately 90% of the 
world´s human population is infected with one or both HSV and suffer from genital and or 
oral lesions, encephalitis, aseptic meningitis and conjunctivitis. Except for VZV, there is no 
vaccine to prevent herpesviruses [202, 203]. 
Beta herpesviruses, includes human cytomegalovirus (HCMV) and Roseolovirus (Human 
herpesvirus type 6 and 7). They have restricted human host range, and long replication cycle 
with quite slow progression in culture [198, 203-205]. Human cytomegalovirus from this 
subfamily can cause congenital infection which may lead to intrauterine fetus death. 
However, most of the children with congenital HCMV infection are asymptomatic at birth, 
HCMV infection in new born baby is the most common cause of congenital abnormalities, 
occurring in 0.2% to 2.5% of all births [206]. The HCMV infection most commonly causes 
hearing loss in new born, but mental retardation and visual impairment are also observe. 
Other clinical manifestations include growth retardation, seizures, lethargy, microcephaly, 
thrombocytopenia and anemia [206] 
Gamma herpesvirinae viruses are oncogenic viruses and includes Epstein-Barr virus (EBV) 
and Rhadinovirus (Human herpesvirus type 8), which is also named Kaposi’s Sarcoma-
associated herpesvirus (KSHV) as the endothelial cells in vessels are infected by HHV8. All 
members of this group replicate in lymphoblastoid cells, and also cause lytic infections in 
some types of epithelioid and fibroblast cells. Viruses in this group are usually T- or B-
lymphocyte specific, and establish latency in these cells [203-205]. EBV from this sub family 
is linked to the etiology of several lymphoid and epithelial malignancies such as 
nasopharyngeal carcinoma, Burkitt's lymphoma (BL), post-transplant lymphomas and gastric 
carcinomas [207]. 
1.2.4 HCMV structure 
HCMV is the largest of herpesviridae and a typical herpesvirus, with a virion size varying 
from 200 to 300 nm. The virion, (virus particle), consists of an icosahedral nucleocapsid 
made of 162 capsomers surrounded by an unstructured proteinaceous layer called the 
tegument. The tegument is enclosed by a lipid layer envelope derived from the host cell 
membrane and containing viral glycoproteins that are involved in attachment and entry into 
cells [208, 209]. 
1.2.4.1 Genome 
HCMV genome consists of approximately 235 kbp, containing 252 open reading frames 
(ORFs) which are believed to encode 180 proteins. However, one recent study suggests that 
HCMV may encode 751 proteins indicating that HCMV may be far more complex than 
previously believed even though the functions of most of these proteins are still unknown 
[210].  
The HCMV double stranded DNA genome, composed of unique long (UL) and unique short 
(US) domains, which are flanked on one end by terminal repeated sequences (TRL and TRS) 
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and on the other end by internal repeats (IRL and IRS) [211].The genome of HCMV contains 
only one origin of replication (oriLyt), in the UL sequence [65, 209, 212, 213]. 
Recombination between the terminal repeats and the internal inverted repeats leads to 
inversion of the UL and US sequences which results in the formation of different viral 
isomers during replication of herpesviruses [214]. 
The HCMV genome, exists as an episome during infection. The episome is associated with 
nucleosomes in the infected host cells but the viral DNA lacks histones when it is 
encapsidated into the virion [215]. It was reported that the host cell nucleosome deposition 
machinery, targets HCMV DNA in infected cells, resulting in a stepwise and dynamic viral 
chromatin assembly [216]. 
 
Fig 3: HCMV virion and outline of genome , Adopted from: 
http://virologytidbits.blogspot.se/2016/01/human-cytomegalovirus-hcmv-and.html 
 
1.2.4.2 Capsid 
The capsid or nucleocapsid is the innermost core layer of a virion particle which contains and 
protects the viral genome. The nucleocapsid shows underlying icosahedral symmetry and 
made of 162 capsomers. The capsid is composed of at least five virus core proteins including, 
Major Capsid Protein (UL86), Minor Capsid Protein (UL85), Smallest Capsid Protein (SCP, 
UL48- 49),  Assembly protein (Fragments of UL80) and Minor Capsid Binding Protein 
(MCP, UL46)[217]. 
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Based on capsid assembly during viral replication, there are three types of HCMV capsid 
present in the nucleus of infected cells, the A-capsid which is only a capsid shell, the B-
capsid which is a capsid shell with assembled proteins and the C-capsid which is a mature 
capsid including the viral genome and immune-evasion [218]. 
1.2.4.3 Tegument 
The nucleocapsid is enclosed by the tegument which is an amorph protein coat for the capsid 
and contains the majority of virion proteins [219]. Most of these tegument proteins are 
phosphorylated, thus often designated with a prefix pp and are highly immunogenic [220] 
[221]. The most studied tegument proteins are pp65/ppUL83, pp71/ppUL82, pp150/pUL32 
and pp28/pUL99. In addition, tegument also contains additional proteins in small amounts 
and some cellular and viral RNA. These proteins play major roles during virus entry, 
intracellular capsid transportation and assembly [222]. Many of host encoded proteins are 
also found in the viral tegument [220]. 
1.2.4.4 Envelope 
The viral envelope is a lipid bilayer which surrounds the tegumented capsid, contains both 
viral glycoprotein and host cell proteins. It interacts with the host cell membrane on target 
cells and thereby plays a major role during virus attachment and entry. The phospholipid 
envelope contains several virus encoded glycoproteins, including gpUL55 (gB), gpUL73 
(gN), gpUL74 (gO), gpUL75 (gH), UL100 (gM), gpUL115 (gL) and pentameric complex 
consisting of gL, gH and UL128-131. These glycoproteins play essential roles in virus entry 
into host cells, cell-to-cell spread, and virion maturation [223, 224]. 
1.2.5 HCMV entry 
In general terms, the process of enveloped virus’s entry requires an attachment to the host cell 
surface, including interaction between virus particle and a host cell receptor, internalization of 
the particle or fusion of the viral envelope with the cell membrane of the host cells.   
Although the cellular targets of HCMV infection is not completely understood, the extensive 
expression of cell surface receptors in permissive cells, include, proteoglycans, cellular 
integrins (specifically αvβ3), and epidermal growth factor receptor (EGFR), β2 
microglobulin, annexin II, aminopeptidase (CD13) and platelet derived growth factor 
receptor-α (PDGFR-α), suggest that multiple cell types support viral entry [225-228].  
HCMV encodes at least 57 glycoproteins, 14 of which have been biochemically proven to be 
the structural components of the virion [221]. The main HCMV glycoprotein complex which 
have important functions during attachment and entry of the virus into the host cell including, 
gB, gH, gL ,gM, gN, and gO are also involved in immune evasion and determination of host 
cell tropism [229-231]. Glycoprotein B (gB) is one of the most abundant HCMV 
glycoproteins. As the major viral envelope constituent, HCMV-gB is involved in attachment 
to the cells via binding to cellular receptors including heparin sulphate proteoglycan (HSPG), 
integrin (αVβ3) and epidermal growth factor receptor (EGFR), annexin II and Toll-like 
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receptor 2, to promote the entry process [226, 227, 232-235]. Glycoprotein B is also involved 
in viral fusion and essential for the infection of all types of target cells [236]. In essence, gB 
is an attractive target for inclusion in a human vaccine and a major focus of experimental 
vaccination strategies [237]. The heparan sulphate proteoglycan molecule allows the HCMV 
particle to attach closer to the cell membrane where viral glycoproteins gB and gH/gL bind to 
specific receptors for cell-to-cell contact and for sufficient viral entry [238-240]. In addition, 
HCMV-gH act as a co-receptor by interacting with integrin αVβ3 [238, 241]. HCMV gH and 
gL associate with a large, heavily glycosylated viral glycoprotein gO and facilitate HCMV 
entry into fibroblasts independent from pH in cell culture [242].  
Several other viral protein complexes are also involved in the viral entry process, including a 
homodimer of gB called gC-I, and a hetero dimer composed of gM and gN that form gC-II 
and a heterotrimer of gH, gL and gO that forms the gC-III complex [242-244]. It has already 
been shown that there is a number of genes from a laboratory strain HCMV which are 
important for entry into endothelial and epithelial cells [245, 246]. Three of these proteins, 
UL128, UL130, and UL131, bind gH/gL to form a quinary complex that functions in entry 
into these cells [224]. These accessory proteins may stimulate a transient interaction between 
gH/gL and gB to induce membrane fusion [247]. HCMV entry into endothelial cells depends 
on gB, gH/gL/gO glycoprotein in addition to envelope pentamer complex (PC) composed of 
gH, gL, UL128, UL130, and UL131A[238, 246, 248-253]. 
The role of HCMV gH/gL has not yet been completely defined but it has been shown to 
promote efficiency of fusion via selected entry pathways important for cellular tropism [254]. 
In conclusion, over the past years it has been recognized that there are distinct routes of 
HCMV entry into fibroblasts, endothelial and epithelial cells depending on an intricate 
interplay of different sets of envelope glycoprotein complexes. HCMV has two different 
entry routes in different cell types, in fibroblasts, viral entry into the target cells requires 
glycoprotein complexes composed of gB and gH/gL/gO and in endothelial and epithelial 
cells, viral entry requires gB, gH/gL/gO glycoprotein in addition to envelope pentamer 
complex (PC) composed of gH, gL, UL128, UL130, and UL131A [238, 246, 248-253]. 
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Fig 4: Human cytomegalovirus entry into cells, Figure from Adam L Vanarsdall and 
David C Johnson, 2012. 
 
1.2.6 Viral replication 
After virus fusion with the cell membrane, the HCMV nucleocapsid is deposited into the 
cytoplasm and viral DNA delivered into the host cell nucleus. Following infection, the viral 
genome is transcribed in a highly regulated sequence, resulting in the serial transcription of 
three different classes of the protein; immediate-early (IE), early (E), and late (L) [255] 
HCMV-IE proteins are the most abundant proteins which are expressed in the first step of 
viral replication cycle; it takes around 4 hours following infection, while the complete 
replication of HCMV yielding complete viral progeny, requires 48-72 hours. Expression of 
IE proteins regulates the subsequent expression of other viral genes (E and L genes), by 
acting as trans-activators or auto-stimulators. E proteins mostly affect the transcriptional and 
replication machinery for the viral protein production and interact with the host DNA. The L 
proteins are mainly structural components (capsid, tegument and envelope proteins) of the 
virions and also include proteins essential for virion assembly and egress [255, 256]. 
HCMV encodes its own proteins for the replication machinery such as a DNA polymerase 
(UL54) and DNA primase (UL70) to sustain an efficient production of new virus progeny 
[257]. 
The HCMV DNA replication is a bidirectional process followed by a rolling circle 
mechanism which originates from a cis-acting lytic origin of DNA replication (OriLyt) 
element to generate viral DNA molecules to be incorporated into new virus particles [258, 
259]. 
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1.2.7 Viral assembly 
When the replication cycle is completed, viral DNA is inserted into the preformed capsids 
and become a mature capsid. This nucleocapsid is exported through various cellular 
compartments (ER and Golgi complex) where it acquires the tegument and envelope [217].  
It is unclear how tegumentation takes place, but as no capsids in the nucleus are tegumented, 
while all are in the cytoplasm, the tegumentation must take place during or rapidly after 
nuclear egress. The tegumented particle then egress to cytoplasmic vacuoles for final 
envelopment [260]. The virions are released/transferred through cell lysis or cell-to-cell 
contact [217]. It has already been shown that Golgi-derived secretory vacuoles containing 
mature virus particles also fuse with the plasma membrane resulting in release of new 
infectious viral particles from infected cells [260]. 
 
 
Fig 5: Life cycle of HCMV in a human cell, Figure from Crough T and Khanna R., 2009 
 
1.2.8 Latency and reactivation 
Viral latency is a central strategy by which herpesviruses ensure their life-long persistence 
without destroying the host. Latency is an interaction between virus and host cell that allows 
a latent state which can change into an initiation of productive replication in response to host 
cues. However a number of fundamental questions about the nature of HCMV persistence 
and the mechanisms regulating this latency and reactivation remains poorly understood [261] 
During primary infection, HCMV infects various cell types including macrophages, 
endothelial cells, epithelial cells, fibroblasts, stromal cells, neuronal cells, smooth muscle 
cells, microglial cells and hepatocytes [225, 262-264]. While some cell types support viral 
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replication, other cell types such as hematopoietic progenitor cells (HPCs) and cells of the 
myeloid lineage (e.g. CD14+ monocytes), harbor viral genomes in the absence of active 
replication, providing latent reservoirs for the virus [265, 266]. Smooth muscle cells and 
endothelial cells have also been implicated as sites of HCMV persistence and latency. It is 
believed that the replication of HCMV in these two cell types play an important role in 
enabling the virus to maintain a life-long infection within the host [267-269]. 
During latency, the viral genome is maintained with a limited latency-associated transcription 
program which does not result in the production of viral particles [270]. It is now relatively 
well established that the differentiation-dependent reactivation of HCMV in the myeloid 
lineage is associated with changes in posttranslational modifications of histones around the 
major HCMV lytic promoter, namely, the major immediate early promoter (MIEP). These 
changes result in major changes in MIEP gene products and initiate the lytic transcription 
program and the production of infectious virions [215, 270-272]. 
It has also been shown that the establishment of murine cytomegalovirus (MCMV) latency, in 
vivo, is associated with repression of immediate early gene expression, deacetylation of 
histones bound to MIEP and changes in methylation pattern of histones bound to MIEP, and 
also recruitment of cellular repressors of transcription to the MIEP [273, 274]. 
In vitro studies showed that, latently infected monocytes have to differentiate into 
macrophages or dendritic cells in order to induce reactivation of HCMV after which the virus 
then enters a lytic phase [270, 275]. It is becoming apparent that the reactivation process is 
orchestrated by both cellular and viral factors, extracellular signals resulting in epigenetics 
alterations [276-279]. 
1.2.9 HCMV different strains 
The first complete HCMV genome sequence, derived from the highly passaged laboratory 
strain AD169, was published almost 28 years ago, in 1990 [280, 281]. Since then, many 
researchers have sequenced various strains of HCMV [282]. The structure and genetic 
content of wild type HCMV have not been well studied, however. Most studies were done on 
HCMV strains which are extensively passaged in human fibroblast cells, even those 
performed to compare the complexity and variations of HCMV genome sequences. A low 
passage clinical strain, denoted Merlin, is today considered as the reference genome (NCBI 
GenBank accession NC_006273.2). According to clinical data, different HCMV strains 
exhibit different levels of virulence depending on their passage history in cell culture and 
competencies in tropism for endothelial and epithelial cells. These differences could be 
attributed to the possible loss of genetic information in these viral strains during propagation 
in cells [283]. 
AD169 and Towne are the most studied HCMV strains originating from wild type virus and 
are extensively passaged in human fibroblasts (HF). These two attenuated viral strains were 
developed as vaccine candidates and used in clinical trials [284]. In contrast, the Toledo strain 
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which is a low-passaged HCMV strain, has produced clinically apparent disease when 
administered to healthy adult volunteers [285].   
Analyses have shown that almost all strains passaged in fibroblasts, have lost all or part of the 
UL128L region and genes of the RL11 family, indicating a possible role in cell tropism for 
these gene products. UL128L consists of the genes UL128, UL130, and UL131A and its 
products form a complex with the viral glycoproteins gH and gL. While this complex is 
unessential for growth in fibroblast it is essential for endothelial and epithelial cell tropism 
[248, 286]. The RL11 gene family contains 14 genes at the 5’ end of the UL region (RL5A, 
RL6, RL11-UL1, UL4 -UL11) that are essential for growth in fibroblasts and are functionally 
poorly characterized [287-289]. 
HCMV strains, Towne and AD169 have substantial deletions (13 and 15 kb respectively) in 
the long unique region (UL) of the viral genome, combined with a compensating expansion 
of the long terminal repeats, TRL/IRL [290]and has several different additional mutations, 
which have important functional consequences for viral cell tropism and infection [291-293]. 
AD169 has open reading frame (ORF) disrupting mutations in genes RL5A, RL13, UL36, 
and UL131A; Towne is affected in genes RL13, UL1, UL40, UL130, US1, and US9 [287, 
291, 294-296]. Even the low-passage strain Toledo is mutated in genes RL13, UL9 and 
UL128 genes [297]. 
 
Fig 6: HCMV ORF organization, adapted from Eain Murphy, et al. 2003 
 
1.2.10 Treatment 
In spite of examining a variety of vaccine strategies, there is not yet any available vaccination 
against HCMV [298]. To date, five licensed antiviral drugs are used for the prevention and/or 
treatment of HCMV infections: ganciclovir, valganciclovir, foscarnet, cidofovir and 
fomivirsen [299]. 
- Ganciclovir and Valganciclovir 
Ganciclovir (GCV) was the first antiviral drug available for HCMV treatment. GCV is a pro-
drug and an analogue of guanosine that is first monophosphorylated by viral UL97 kinase and 
then become di- and triphosphorylated by a cellular kinase. This ensures that only infected 
cells are treated. This triphosphorylated guanosine analogue incorporate into the viral DNA 
chain and inhibits viral DNA polymerase and viral DNA synthesis. Ganciclovir is available in 
oral and intraocular formulations [299]. Valganciclovir (VGV) is a pro-pro-drug and 
available as an enteral formulation that rapidly metabolize to the active form, ganciclovir, in 
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the liver and intestinal wall [300, 301]. GCV resistance, which commonly occurs after solid 
organ transplantation, can be caused by mutation in the viral protein UL97, 
phosphotransferase, genes or the UL54 (viral DNA polymerase gene). More than 90% of 
isolates contain one or more mutations in the UL97 gene. The major side effect of GCV 
involves hematological abnormalities, particularly neutropenia but also toxicity effect on the 
liver and kidney [299]. 
 
Fig 7: Mechanism of Ganciclovir function in CMV infection, adapted from 
https://www.google.se/search 
 
- Foscarnet 
Foscarnet is used for those who cannot be treated with GCV due to dose limiting neutropenia 
or leucopenia, or due to resistance to GCV [302]. It has been suggested that this drug 
selectively inhibits the pyrophosphate binding site on viral DNA polymerase and inhibits its 
function and does not require cellular or viral kinases to be activated [303]. 
- Cidofovir 
This drug is used only as a second line therapy, due to its side effect. Cidofovir requires 
cellular kinases to be activated and causes premature termination in viral DNA synthesis and 
inhibits viral DNA polymerase [304, 305]. 
- Fomivirsen 
Fomivirsen can block all classes of HCMV gene expression as it is an antisense 
oligonucleotide inhibitor of HCMV-IE mRNA. This drug is used for treating HCMV retinitis 
in immunocompromised patients, mostly HIV patients [303]. It has a half-life of 
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approximately 55 hours, which allows infrequent dosage and due to its intraocular 
administration, it has no systemic effect during treatment [306]. 
- Novel inhibitors of HCMV 
Although drugs currently available for the treatment of HCMV disease has proven successful 
in immunocompromised patients, their use is limited. This limitation is due to their side 
effects, toxicity, poor oral bioavailability, modest efficacy and the development of drug 
resistance. In some cases, such as pregnant women or congenitally infected patients, these 
drugs should not be used due to their teratogenic effects. Therefore, there is a need to develop 
new compounds against HCMV diseases with alternative mechanisms of action e.g. the 
disruption of other steps in viral propagation such as attachment, entry, viral gene expression 
and function [303, 307].  
Currently, there are some new drugs in preclinical studies: 
- Maribivir is an inhibitor of HCMV UL97 kinase. UL97 is an important molecule that digest 
the nuclear lamina, and inhibition of UL97 prevents the maturation of capsid required for the 
egression from the nucleus to cytoplasm [308]. It has undergone phase-II trial and it has 
failed in phase-III. Further, Maribivir cannot be used with GCV due to its antagonizing effect 
on the drug [309, 310]. 
- Brincidofavir is a lipid prodrug of Cidofovir. Even though it has no renal toxicity as 
compared to Cidofovir, it has certain gastrointestinal toxicity, manifested as diarrhea [311]. 
- Letermovir is a unique antiviral drug which inhibits the viral terminase enzyme. Packaging 
of herpesviral DNA is believed to be mediated by the terminase enzyme which includes 
cleavage of viral DNA and packaging into the capsid. Inhibition of viral terminase by 
Letermovir prevents packaging of viral capsid containing viral DNA [312].  
A recent publication identified the endothelin B receptor antagonist, Macitentan, which could 
be a potential future treatment option for HCMV infection [313]. Currently, this drug is used 
for treatment of patients with pulmonary hypertension and blocks HCMV infection in vitro 
by interfering with receptor binding, signaling and transcription of HCMV IE proteins [314]. 
 One study showed that a potent and selective small molecule, CF102, can inhibit gB 
mediated HCMV virion fusion and cell-cell spread. CF102 acts very early after infection in 
the replication cycle and inhibits virion envelope fusion with cell plasma membrane. CF102 
is not being developed clinically due to in vivo stability and metabolic issues [235]. 
1.2.11 HCMV and cancer 
1.2.11.1 Oncoviruses 
Approximately 12% of all human cancers are caused by oncoviruses [315]. Although a large 
number of the world’s population harbors at least one of these oncoviruses, these infections 
rarely result in cancer [316]. Oncoviruses are classified as direct and indirect carcinogenesis, 
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even some overlap exist in between [317]. Direct carcinogenesis includes viral oncogenes 
that directly contribute to transformation and cellular neoplasticity, whereas indirect 
carcinogens cause chronic inflammation and subsequent oncogenic transformation through a 
number of steps [318]. In fact, oncoviruses encode gene products that can induce cellular 
transformation under certain circumstances [319-321]. Currently, there are seven recognized 
human oncoviruses which include Epstein - Barr virus (EBV), Human Papillomavirus (HPV), 
Hepatitis B and C viruses (HBV and HCV), Human T-cell lymphotropic virus-1 (HTLV-1), 
Human Herpesvirus-8 (HHV-8), and Merkel Cell Polyomavirus (MCPyV) [322]. EBV is 
linked to the etiology of several different lymphoid and epithelial malignancies, such as 
nasopharyngeal carcinoma, Burkitt's lymphoma (BL), post-transplant lymphomas and gastric 
carcinomas [207].  
Many oral and other anogenital malignancies as well as over 99% of all cervical cancers are 
associated with high-risk HPV infections (HPV 16-18)[323]. 
Hepatitis B and C viruses (HBV and HCV) both are hepatotropic viruses known to be a risk 
factors for hepatocellular carcinoma (HCC) [324].  
Some other viruses are connected to different neoplastic diseases, e.g. Human T-cell 
lymphotropic virus-1 (HTLV-1) are linked to adult T-cell leukemia (ATL) [325], Human 
Herpesvirus-8 (HHV-8) to Kaposi’s sarcoma (KS) and primary effusion lymphoma [207], 
and Merkel Cell Polyomavirus (MCPyV) are linked Merkel cell carcinoma (MCC) which is 
an extremely rare and aggressive cutaneous cancer [322]. 
Although all these viruses do not belong to the same family of viruses they have the ability to 
infect and remain in the host cell without completely destroying it. They establish persistent 
and long term infections, and importantly, have strategies to evade the host immune system 
[326]. 
1.2.11.2 Prevalence of HCMV in cancer 
The concept of a role of HCMV in cancer is not new. The presence of HCMV in prostate 
cancer was reported by Fred Rapp’s group in the 1970s. They isolated a HCMV strain from 
tumor that was oncogenic in vitro and in immuno-deficient mice [327]. Later and over the 
previous years, HCMV proteins and nucleic acids have frequently been detected in tissue 
specimens from patients with cancers of different origin, including colon [2], breast [3], 
prostate [4], mucoepidermoid salivary gland tumors [5], medulloblastoma [196], 
glioblastoma [1, 328, 329], neuroblastoma [330] and rhabdomyosarcoma [6]as well as 
metastatic tumors [331, 332]. Although HCMV proteins were mainly detected in tumor cells, 
and sometimes in endothelial or inflammatory cells adjacent to the tumor, no or little of 
HCMV IE proteins were found in the healthy tissue surrounding the tumor tissue [2]. 
One recent study isolated a clinical HCMV strain denoted HCMV-DB [333] which can 
transform human mammary epithelial cells (HMECs) in vitro and in vivo. Infection of 
HMECs cells with HCMV-DB was followed by the inactivation of retinoblastoma and p53 
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proteins, the activation of telomerase, the activation of the proto-oncogenes c-Myc and Ras, 
the activation of Akt and STAT3, and the upregulation of cyclin D1. These data suggest that 
the key molecular pathway which are involved in oncogenesis are activated by HCMV-DB 
infection in HMECs [334]. Although the presence of HCMV has been shown in different 
malignant tissues, its importance is still a matter of debate [335]. It is not yet well understood 
if the virus plays a causative role in these cancers, or just simply represents an 
epiphenomenon [182]. 
1.2.11.3  Oncomodulation effect of HCMV  
Cancer is a term used for diseases in which cells abnormally divide and grow and are able to 
invade nearby tissues. These cancer cells can spread to other parts of the body through the 
blood and lymph system and may results in metastatic disease which is usually incurable. As 
mentioned above in this thesis, several lines of evidence in cancer biology indicate that the 
tumorigenesis is a multistep process and several hallmarks of cancer have been identified 
comprising, uncontrolled and sustained cell growth, insensitivity to negative growth 
regulation, resistance to induced cell death, lack of senescence, genomic instability, 
angiogenesis and invasion and metastasis [133]. 
 As described above, several studies indicate the presence of HCMV in different types of 
cancer. On other hand, different proteins which are encoded by HCMV indicate that HCMV 
is a complex virus even though the function of most of these proteins are still unknown [210]. 
Although HCMV proteins have been found in several cancer tissue specimen, it is not 
considered as a typical oncogenic virus [336]. The term oncomodulatory has been proposed 
for HCMV to describe the influence of the virus in tumorigenesis [319-321]. 
Oncomodulation is the ability of the virus to promote an oncogenic process characterized by 
disruptions in intracellular signaling pathways, transcription factors and tumor suppressor 
proteins in an appropriate genetic/epigenetic environment. In fact, HCMV infection leads to 
chromosome instability, control of the cell cycle and inducing telomerase activity, 
angiogenesis and cellular migration, and inhibiting apoptosis [320, 337].  
It has already been reported that HCMV infection causes a rapid activation of host cell 
mitogen pathways, e.g. the PI3K pathway in human fibroblasts. It was also shown that PI3K 
activation is important for initiation of viral DNA replication, which results in cellular 
proliferation [338]. Mutation of one or several genes in the P13K pathways in cancer cells 
can lead to consistent activation of the pathway, to stimulate growth, survival and 
proliferation in these cells [339]. 
HCMV has developed multiple mechanisms to ensure activation of the MAPK in infected 
cells, a kinase that is known to be critical for viral infection [340]. Another study reported the 
role of HCMV-US28 protein (a constitutively active chemokine receptor homologue) in 
tumor development through induced activation of STAT-3, induction of IL-6, vascular 
endothelial growth factor (VEGF), and cyclooxygenase-2 (COX-2) both in vitro and in vivo 
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positive cells. These factors play important roles in tumor progression, angiogenesis, tumor 
cell migration [341, 342]. 
HCMV infection in the cells induce specific chromosomal breaks, p53 mutation and take 
control of epigenetic functions [336, 343, 344].  
The HCMV IE protein can bind to p53, Rb and degrade p21 and thereby modulate cell cycle 
regulation and down regulate tumor suppressor proteins [345]. It has also been reported that 
HCMV proteins IE72, IE86 [346], pp71 [347] and UL97 [348] are involved in inactivation of 
the Rb tumor suppressor protein family, and promoting the cell cycle to enter S phase. 
Furthermore, HCMV IE proteins activate cell survival pathways in both in normal and tumor 
cells trough induced expression of the transcription factor NFkB [349]. 
HCMV IE proteins also induce cell cycle regulation and cellular division by expressing 
proto-oncogenes, cyclins and kinases [350].Most notably, it was shown that HCMV can 
induce chromosomal break at 1q42 and 1q21 in a replication-independent manner [351]. The 
possible targets residing near 1q42 include the ADPRT locus associated with DNA repair and 
replication [352]. This deletion has been connected to the development of glioblastoma [353] 
It has been proposed that HCMV has modulated multiple ways to promote angiogenesis, 
which is a very important component of solid tumor development [354]. Cell-free 
supernatants obtained from HCMV-infected cells contain higher levels of pro-angiogenic 
molecules and promote angiogenesis in vitro [355]. 
In infected glioma cells, HCMV IE induce angiogenesis either via suppression of TSP-1 
expression, thrombospondin-1, anti-angiogenic factors or via induced production of IL-8 
[356, 357]. It has already been shown that in HCMV infected glioblastoma cell, HCMV gB 
proteins bind to PDGFR-alpha which results in intracellular phosphorylation of the receptor 
and enhancing migration and angiogenesis [228]. Furthermore, HCMV protein can promote 
stemness by blocking cellular differentiation and interact with the DNA damage response 
pathway to alter the cell cycle [321]. 
1.2.12 Viral infection and epigenetic modification 
DNA viruses including polyomaviruses, adenoviruses, papillomaviruses, herpesviruses, and 
hepatitis B virus, exist as an episome in the nucleus of the host cell. These viruses likely 
exploit epigenetic mechanism to regulate biological activities during their life cycle for the 
following reasons:  
1- These viruses typically assemble into some form of nucleoprotein structure and varieties of 
chromatin in the nucleus, to avoid DNA damage signaling and nucleolytic attack [358]. 
2- As an obligate intranuclear parasite, the viruses usually use the cellular protein synthesis 
machinery, regulatory factors, co-factors and enzymes to accomplish gene expression and 
regulation. 
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3- These viruses require epigenetic or similar processes to allow for the different viral 
genome states necessary to complete an infection and to coexist with the host. 
In other hand, the viruses may also epigenetically dysregulate host cell biology to enhance 
their own biological process, e.g. by stimulate the synthesis of factors associated with DNA 
replication, transcription or inhibit pathway involved in immune surveillance [359]. 
 
Fig 8: Hallmark of cancer, adapted from Hanahan & Weinberg, 2011 
 
1.2.12.1 Herpesviridae and epigenetic modification 
A number of the Herpesviridae family are significant human pathogens including, herpes 
simplex virus (HSV), Epstein–Barr virus (EBV), and Kaposi’s sarcoma-associated 
herpesvirus (KHSV) [360]. Depending of the cellular environment, infection by 
herpesviruses can result in either lytic or latent infection. In lytic infection, the infected cell is 
ultimately killed. In contrast, in a latent infection, the virus exists as an episome in the 
nucleus of the infected cell, coordinate its own replication with the host, and segregate itself 
along with the chromosomes of the cell following replication [359]. [359]. In fact, during 
latency, the viral genome is in a heterochromatic state and viral transcription is suppressed. 
This silenced genome can be reactivated and allowing viral lytic gene expression by initiating 
the expression of IE genes. 
This aspect of regulation is generally controlled by a viral protein, which interacts with the 
cellular chromosomes to tether the newly replicated virus for segregation along with the 
chromosome [361]. There must be a way for the virus to be in a latent phase and to reactivate 
and generate a lytic infection. This reactivation process is usually a result of changes in the 
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cellular environment and thought to contribute to epigenetic changes. During this process, a 
number of histone modification enzymes such as histone demethylases, plays important roles 
in driving IE expression even if the mechanisms involved in this process is not fully 
understood [361]. A recent study show that in lytic infection, histone demethylases which 
reverse the repressive histone H3-lysine 9 and lysine 27 methylation, are important in the 
activation of viral IE gene expression [361].  
KSHV has been extensively studied due to its ability to cause cancer in AIDS patients. Upon 
infection by the KSHV virus, the chromatin structure is organized and allow for immediate-
early transcription with corresponding histone modifications activating the appropriate genes 
and deactivating other genes [362]. Shortly after infection, the transcription factor which is 
involved in activating the lytic form of the virus is repressed and Latency Associated Nuclear 
Antigen (LANA) is produces along with a small number of other viral genes [363]. There is a 
gross change in chromatin structure of the virus upon reactivation [362]. There is also 
evidence from next-generation sequencing, showing that gene silencing in repressive 
chromatin may also occur through DNA methylation and interactions with noncoding RNAs 
in KSHV [364]. 
Similar to KSHV, it seems that epigenetic factors also regulate both HSV and EBV 
reactivation and latency. In HSV, lytic infection initiates with the chromatinization of the 
viral DNA, which occurs in 1-2 hours after infection. The chromatin is acted upon by 
transcription factors from the virus and the cell, along with chromatin remodeling factors. 
The chromatin modifications include changes in histone modification and nucleosome 
positioning resulting in immediate early gene expression. In latent infection, viral DNA is 
chromatinized more slowly and the genes responsible for completion of a lytic infectious 
cycle, appear to exist as heterochromatin with repressive histone modifications such as 
H3K27Me3histone modifications [358, 362-365]. 
As EBV plays a causing role in certain human cancers such as Burkitt´s lymphoma and post-
transplant lymphoma [207], it has undergone some very extensive analyses of epigenetic 
modifications. The results showed certain histone modifications and gene expression or 
repression. For example, methylated H3K4 was located at sites of gene expression and the 
location of RNAPII, transcription factor [366]. In general, DNA methylation of the EBV 
genome, results in silencing of genes, however there are significant differences within various 
latency types with respect to genes silenced [367]. 
1.2.12.2 HCMV infection and epigenetic modification 
As other DNA viruses, the HCMV genome exists as an episome in association with 
nucleosomes in infected cells, but during encapsidation into virions, the viral genome is 
believed to be completely free of histones [215, 216]. In recent years, accumulating evidence 
strongly suggests that the assembly and modulation of chromatin association with the viral 
genome is an additional layer in the regulation of viral gene replication and transcription 
[368]. 
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In other words, the host cell nucleosome deposition machinery targets HCMV DNA upon 
infection, resulting in a stepwise and dynamic viral chromatin assembly process. This finding 
suggests that epigenetic events are involved in all viral DNA functions during HCMV 
infection such as genome replication, DNA damage response and the temporal cascade of 
viral gene transcription [216]. Recent studies showed the close interaction between HCMV 
encoded proteins and cellular epigenetic mechanism [368-370]. Indeed, previous studies have 
shown that post-translational chromatin remodeling is associated with the differentiation and 
maturation of non-permissive and un-differentiated CD34+ cells with an inactive major 
immediate-early promoter (MIEP) towards antigen presenting permissive cells such as 
dendritic cells and macrophages, resulting in reactivation of latent HCMV starting with the 
MIEP [371-373]. At latency, HCMV-MIEP is associated with transcriptional suppression 
factor (HP-1), which binds to methylated histones and at lytic phase of infection, this factor 
binds to acetylated histones, which is a marker of transcriptional activity [215]. Moreover, 
HCMV-MIEP and entire HCMV-IE locus binds to HDAC3 [374]. During reactivation of 
latent HCMV infection, the chromatin is remodeled and the histones are acetylated with 
subsequent viral gene expression [375]. 
In addition, another study suggested that the HCMV tegument protein, pUL97 kinase 
regulates viral immediate early gene expression by phosphorylation disruption of HDAC1 
and binding to the IE promoter [376]. 
 
1.3 CNS TUMOR 
1.3.1 - Medulloblastoma (MB) 
Medulloblastomas (MB) are a compilation of molecularly diverse tumor types that originate 
either in the cerebellum or brain stem. Medulloblastoma of the cerebellum accounts for 20% 
of malignant childhood brain tumors. This type of tumor mainly occur in infancy and 
childhood, although it can rarely occur in adulthood. The etiology of MB is not fully 
understood but the impact of environmental factors such as diet, pathogens, exposure to 
radiation and hereditary genetic defects have previously been reported [377].  
The evidence from gene expression profiling supported the existence of four main subgroups 
of medulloblastoma; Wnt, SHH, Group 3 and Group 4. The Wnt and SHH (Sonic Hedghog) 
were named for the signaling pathways that play major roles in the pathogenesis of these 
subgroups. The generic names for the remaining two groups were chosen since the biology 
underlying these subgroups were less known until relatively recently [378].  
- WNT subgroup 
The best known subgroup of medulloblastoma is the WNT subgroup due to its very good 
prognosis and long term survival [379]. Nearly all of the Wnt medulloblastomas studied to 
date have classic histology [380], germline mutation of the Wnt pathway and the 
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adenomatous polyposis coli (APC), in addition to somatic mutations of CTNNB1 encoding 
β-catenin, which have been found in sporadic medulloblastomas [381, 382]. TP53 mutations 
are identified in approximately 15% of WNT medulloblastomas but are not associated with 
poor prognosis [383] 
- SHH subgroup  
Approximately 25% of medulloblastoma occurrences are SHH subgroup tumors [384]. SHH 
signaling is required for normal cerebellar granule neuron precursors (CGNP) proliferation 
during development. Germline mutations in the Shh receptor [385], similarly, somatic 
mutation of SHH pathway genes such as PTCH, SMO, and SUFU as well as amplifications 
of downstream transcription activators, GLI1 and GLI2, have been found in this subgroup of 
medulloblastoma [386-388]. These mutations, causing constitutively active SHH signaling 
and increased downstream target gene expression, are drivers of SHH medulloblastoma [389, 
390]. A part of childhood medulloblastomas contain TP53 mutations and these patients have 
the worst outcome although patients with adult or childhood SHH medulloblastoma with 
wild-type TP53 have intermediate prognosis [390, 391]. Another mutation in TERT 
(telomerase reverse transcriptase) promoters has been reported in SHH medulloblastoma 
patients, which is associated with better treatment outcomes [391-393]. MYC genes are 
amplified in 10% of medulloblastomas [394, 395] aberrant expression of these genes has 
been shown to lead to tumorigenesis [396]. 
The prognosis of SHH subgroup of medulloblastoma appears to be intermediate between the 
Wnt subgroup, with very good prognosis, and Group 3 which is poor [397-399]. 
- Group 3 
Group 3 represents roughly 25% of medulloblastoma occurrences. In this subgroup of 
medulloblastomas, a number of genes that play a role in retinal development are 
overexpressed, although the pathogenetic effect of these genes’ over expression is not 
currently clear [380, 400]. One subset of Group 3, Group 3α, with MYC amplifications 
assume the highest risk of recurrence and death. In contrast, Group 3β, another subset of 
Group 3 which were not found to harbor MYC amplifications, showed intermediate 
prognosis similar to Group 4 [401]. The terrible prognosis for Group 3 patients indicates that 
for this subgroup of medulloblastoma the development of practical biomarkers and 
understanding of the underlying pathogenesis are necessary [378].  
- Group 4 
The Group 4 tumors make up >30% of all medulloblastomas and present with an 
intermediate prognosis, similar to SHH tumors. The molecular pathogenesis of the Group 4 is 
not well understood [378, 380, 401]. Although an isochromosome 17q is common in Group 
4, it is also seen in 26% of Group 3 tumors [380]. The only specific genetic changes among 
this subgroup is loss of the X chromosome, which is seen in 80% of females with Group 4 
medulloblastoma. The over-representation of genes involved in neuronal differentiation and 
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neuronal development has been reported in Group 4, but are not yet clinically understood 
[380, 400, 401]. 
1.3.1.1 Medulloblastoma and epigenetic alteration 
One of the most interesting discoveries from genomic studies of medulloblastoma is the high 
frequency of epigenetic regulator alterations across all four subgroups. More than 30% of 
medulloblastoma samples harbor mutations, deletions, or amplifications of genes encoding 
epigenetic regulators [402-404]. The most studied epigenetic alterations associated with 
human medulloblastoma are DNA methylation and histone modifications. 
- DNA methylation 
Alteration of DNA methylation is a common feature of tumorigenesis [14]. Analyses of 
genome wide DNA methylation arrays suggest that DNA methylation plays a major role in 
pathogenesis of MB by repressing genes associated with cell differentiation and cell death 
[405, 406]. Bisulfite treatment followed by PCR, showed silencing of several tumor 
suppressor genes by hypermethylation of CpG tumor suppressor promoters [407, 408]. Other 
array analysis identified aberrant methylation in some genes, such as the negative regulator of 
SHH signaling, inhibitors of the WNT signaling pathway, and a transcriptional repressor, 
among others [409]. Treatment of medulloblastoma cancer cell lines with DNA methylation 
inhibitors also reveal increases in expression of identified genes, although the samples used in 
this study were not subgroup classified [402]. Recent genome-wide studies of DNA 
methylation patterns in subgroup classified medulloblastoma have provided new insights into 
the tumor molecular pathogenesis. By using methylation microarray, DNA methylation status 
at 1505 loci in 807 genes was analyzed in 230 medulloblastoma samples which were 
previously classified with transcriptome profiles. The data showed that the four subgroups 
identified based on DNA methylation are highly related to their transcriptome counterparts. 
This finding suggests that each medulloblastoma subgroup has a specific DNA methylation 
pattern which can be used as a robust sub-classification standard [410]. It has already been 
reported that an oncogene VAV1 is hypomethylated with elevated expression in most human 
SHH medulloblastoma and mouse SHH medulloblastoma models [411]. Another study 
determined the high expression of DNMT1, DNMT3A and DNMT3B in human 
medulloblastoma samples, suggesting that promoter hypermethylation may play a role in 
medulloblastoma development [412]. Notably, DNA methylation in tumors can be inherited 
from their cell-of-origin neural lineages, but can also be generated de novo in tumors. It is not 
quite clear if these cancer-specific DNA methylation alterations are regulated by the activities 
of DNA methyltransferases and/or enzymes that remove the methyl group, such as TET 
enzymes [406]. 
- Histone acetylation 
Histone modifications including, acetylation, methylation, phosphorylation, and 
ubiquitination may either alter local chromatin structures or, more importantly, recruit 
proteins that recognize the modifications and regulate gene transcription. In 
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medulloblastoma, multiple genes including histone modification enzymes are altered [388]. A 
comprehensive study which analysed more than 1000 medulloblastoma samples, confirmed 
the importance of copy number changes of histone modification in medulloblastoma. 
Recurrent focal amplifications and homozygous deletions in genes targeting histone lysine 
methylation, particularly that of H3K9, were identified in medulloblastoma [413]. The 
mechanism(s) behind these epigenetic changes the impact on medulloblastoma development 
are still unclear [406]. Group 3 and Group 4 medulloblastomas have relatively high global 
H3K27me3 levels [414]. A global high H3K4me3 and low H3K27me3 status is associated 
with better prognosis than low levels of both H3K4me3 and H3K27me3 within Group 3 and 
Group 4 tumors [403].  
In addition, histone acetyltransferases (HATs) and histone deacetylases (HDACs) also have 
important roles in medulloblastoma. It is reported that hMOF, a HAT enzyme, is down 
regulated in many medulloblastoma samples, and this down regulation is associated with low 
survival [415]. The HAT genes are also mutated in some medulloblastoma patients [414, 
416]. 
In general, HDACs likely support medulloblastoma growth, and HDAC inhibitors alone or in 
combination with other inhibitors are being tested in clinical trials for treatment of 
medulloblastoma [417-419]. 
1.3.1.2 Medulloblastoma and HCMV 
Recent studies indicate that HCMV immediate-early and late proteins are expressed in the 
majority of primary medulloblastomas. In addition, this study showed that the anti-viral drug, 
ganciclovir significantly reduces tumor growth in mice carrying established human 
medulloblastoma xenografts [196]. 
Another study from the same group demonstrated that HCMV was detected in 92% 
medulloblastoma. They also showed that engrafted cells containing HCMV nucleic acids in 
nude mice exhibited induced HCMV protein expression, which was correlated with COX-2 
expression in primary tumor cells, cell lines and medulloblastoma xenografts. Most 
importantly, the combination of the anti-viral drug valgancicovir and the COX-2 inhibitor, 
celecoxib prevented HCMV replication in vitro leading to reduced production of PGE2 and 
decreased tumor growth [196].  
It has been shown that HCMV may impact the medulloblastoma host cell replication stress 
and DNA repair [420]. Others showed that HCMV encoded protein US28 promotes cell 
proliferation, angiogenesis and cell cycle progression, which can represent an 
oncomodulatory role of HCMV in medulloblastoma through induced activation of STAT-3, 
induction of IL-6, vascular endothelial growth factor (VEGF), and cyclooxygenase-2 (COX-
2) in US28 positive cells. [421, 422]. 
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1.3.1.3 Treatment of medulloblastoma 
The current treatment for patients with this highly malignant tumor consists of surgery, whole 
brain and spinal cord radiation (in patients above 3 years), and aggressive chemotherapy, 
sometimes followed by stem cell transplantation [413] [406]. Even though the overall 
survival of medulloblastoma patients is relatively high (long-term survival (>5 years) of MB 
patients is 60% - 70%) the patients often experience disease and complications related to 
treatment including developmental, neurological and psychological deficits [423] [406] 
Current treatment for medulloblastoma patients > 3 years of age is based on radiation to the 
brain and spine with a boost to the tumor bed, together with combinations of multidrug 
chemotherapy [423, 424]. A major goal for the children < 3 years of age is to eliminate or 
greatly reduce the radiation to the brain and spine due to the brain development in these early 
age of life. The treatment can consist of surgery dependent on the size of the tumor, and stem 
cell transplantation [425, 426]. High dose chemotherapy in young children and infants 
without irradiation gives nearly 75% overall 5-year survival for favorable subgroups [427]. 
Under such circumstances, a new effective treatments with minimal damage to the 
developing brain in these children is highly relevant.  
Recent comprehensive epigenetic analyses have revealed a deeper understanding of the 
mechanisms of MB pathogenesis [405, 414, 428] and inhibition of DNMTs may result in a 
decreased tumor formation. Therefore, DNMTs could be served as valuable targets for 
designing of specific antitumor agents [429]. 
1.3.2 Glioblastoma (GBM) 
Glioblastoma is an aggressive central nervous system (CNS) malignancy with a median 
survival of 15 months despite significant progress in surgical resection, chemo and 
radiotherapy [430] [431]. The risk factors for GBM are unknown but heredity, environmental 
exposures to radiation, vinyl chloride and pesticides have been considered in the initiation of 
GBM [1, 432, 433]. Even traumatic brain injury involving inflammation has been suggested 
in the etiology of GBM, although this is still controversial [434]. Additionally, HCMV 
infections are considered to be a common risk factor and part of the pathogenesis, although 
this is still controversial. 
1.3.2.1 Glioblastoma and epigenetic alteration 
Besides genetic abnormality, aberrant epigenetic alterations also contribute to GBM [435]. 
Three subgroups of GBM show alteration in both DNA methylation and methylation of 
lysine residue of histone proteins [35, 436]. DNA methylation is however, the most studied 
epigenetic alteration in GBM.  
- DNA methylation 
Epigenomic profiling has revealed aberrant DNA methylation mediates in GBM development 
and malignancy [437]. Epigenetic silencing through promoter hypermethylation of the O6-
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methylguanine methyltransferase (MGMT) gene has been widely described in glioma. 
MGMT is an important repair enzyme which contributes to resistance to temozolomide, a 
chemotherapy using for treatment of GBM patient. MGMT promoter methylation silences 
this gene which results in decreasing DNA repair activity and increasing the susceptibility of 
the tumor cells to temozolomide [438-440]. It is reported that the promoter of several genes 
involved in key cellular functions such as the cell cycle [441], tumor suppression [442], DNA 
repair [443], tumor invasion [444] and apoptosis [445], have been silenced in association with 
promoter hypermethylation in malignant glioblastoma. One single study reported a 
significant overexpression of DNMT1 and DNMT3B in 20 cases of GBMs. This study 
proposed that the overexpression of DNMT1 and DNMT3B in gliomas leads to 
hypermethylation of various tumor suppressor genes, resulting in lack of growth regulation 
and higher genome instability, resulting in poor prognosis in gliomas. This research also 
showed that the DNMT1 gene is differentially regulated by both histone acetylation and 
histone methylation in gliomas. It is evident from this study that histone modifications apart 
from methylation, play a pivotal role in DNMT1 gene expression. [446].  
Furthermore, the link between the 1p/19q co-deletion and epigenetic alterations in the course 
of demethylation/hypomethylation has previously been studied and shown a positive 
association with IDH promoter mutations resulting in production of the oncometabolite R-2-
hydroxyglutarate. Different enzymes, including the epigenetic regulator TET2 enzymes, are 
inhibited by R-2-hydroxyglutarate causing demethylation/ hypermethylation of DNA [447, 
448], specifically, hydroxylation of 5-methylcytosine (5mC) to generate 5-
hydroxymethylcytosine (5hmC) [447].  
The Cancer Genome Atlas (TCGA) research network performed whole genome sequencing 
of GBM tumors and found that GBM recurrence is linked to epigenetic mechanisms and 
pathways [449]. A next generation sequencing analysis revealed a global decrease in 
H3K4me3 in GBM, especially at promoters and CpG islands [450]. 
1.3.2.2 Glioblastoma and HCMV 
HCMV has been detected in 90-100% of GBMs [1] [451] [328]. Similar to medulloblastoma, 
HCMV nucleic acids and proteins were found in majority of patients with high and low grade 
of gliomas. In several studies, the expression of HCMV early and late gene products have 
already reported in these tumors [1, 7, 196]. HCMV DNA has also been detected in 
peripheral blood of glioma patients [451]. A recent study showed that low grade HCMV 
infection in GBM tumors was highly associated with survival longer than 18 months [328]. 
Although the exact role of HCMV in GBM is still under investigation, evidence suggest that 
HCMV plays an oncomodulatory role in GBM and can disrupt certain pathways involved in 
the cell cycle, apoptosis and angiogenesis [452, 453].  
Additionally, the positive effect of antiviral treatment by valganciclovir (Valcyte) in 
glioblastoma patients has been reported. Tumor growth was restricted and survival was 
longer in patients treated with ganciclovir [454]. More than 250 glioblastoma patient were 
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examined and only one of them was HCMV negative. From the 75 patients evaluated in that 
study, the median rate of overall survival was 33 months in those with low-grade HCMV 
infection and 13 months in those with high-grade HCMV infection, while the median rates of 
2-year survival were 63.6% and 17.2%, respectively [454]. 
1.3.2.3 Treatment of Glioblastoma 
The current standard treatment for GBM is resection, radiation, and chemotherapy. Due to the 
highly invasive nature of GBM cells, malignant gliomas cannot be completely eliminated 
surgically [455]. The current combination treatment regime includes the alkylating agent 
temozolomide (TMZ) and radiation [430].  
As mentioned before, O6-methylguanine methyltransferase (MGMT) is an important repair 
enzyme which contributes to resistance to temozolomide. MGMT promoter methylation 
silences this gene and results to decreasing DNA repair activity and increasing the 
susceptibility of the tumor cells to temozolomide. Glioblastoma patients with MGMT 
methylated promoter who were treated with temozolomide had longer overall survival of 21.7 
months. In contrast, patients without MGMT promoter methylation who were treated with 
temozolomide had a significantly shorter median survival [456]. However, TMZ is used in 
the treatment of glioblastomas regardless of MGMT promoter methylation status [455]. In 
addition, GBM cells develop resistance against the current treatment regimen that includes 
TMZ and radiation. [457, 458]. Despite decades of research and treatment, the median 
survival of GBM patients still remains at 15 months [431]. Due to the difficulties in treatment 
of GBM patients, new strategies that effectively target GBM cells and/or overcome their 
resistance to treatment will be necessary [455]. As DNA methylation is a reversible 
epigenetic phenomena and due to overexpression of DNA methyltransferases in gliomas, 
DNMTs may serve as a marker for cancer cells and may be an important target in the 
treatment of glioblastoma [446, 459]. 
  
 34 
 
2 AIM OF THE STUDY 
The aim of this thesis were: 
 
1- To study the impact of HDAC inhibitor on genomic DNA methylation changes. 
2- To investigate the mechanism(s) involved in cellular relocalization of DNMTs 
following HCMV infection. 
3- To study the effect of HCMV infection on host cell DNA methylation in 
malignant CNS tumor. 
4- To determine the role of HCMV for epigenetic alteration in GBM and MB. 
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3 RESULTS AND DISCUSSION 
3.1 STUDY I 
Genomic DNA hypomethylation by histone deacetylase inhibition implicates DNMT1 
nuclear dynamics 
- Background 
 Histone deacetylase inhibitors (HDACi) are considered as antitumor drugs acting through 
e.g. reactivation of silenced tumor suppressor genes. Several HDACi have been developed 
and are currently in clinical trials both for hematological and solid tissue malignancies. 
Accumulating evidence has shown that combination of HDACi and DNA methylation 
inhibitors (DNMTi) represents a promising cancer therapy strategy. There is some evidence 
that synergistic effects of HDACi and DNMTi is achieved by their action on common targets, 
including DNA methyltransferase 1 (DNMT1). Our study aimed to investigate further the 
interaction between HDACi, DNMTi and DNA global DNA methylation. We studied the 
effect of the HDACi, Trichostatin A (TSA) on global and gene-specific DNA methylation 
and applied methods with single molecule sensitivity, confocal laser scanning microscopy 
and fluorescence correlation spectroscopy (FCS), to study TSA effects on the nuclear 
dynamics of DNMT1 in live cells. 
- Results and discussion 
Our study confirmed that TSA causes genomic hypomethylation and involves a decrease of 
nuclear DNMT1 protein levels. By using FCS, we have also shown that both the DNMT 
inhibitor 5AZA and the HDAC inhibitor TSA change the nuclear kinetics of DNMT1. The 
mechanisms behind the TSA effects are apparently different from the mechanisms of action 
of 5AZA. These data show that the effects of HDACi are not limited to direct 
hyperacetylation of histones but may indirectly affect other epigenetic factors, such as 
DNMT1 activity, through converging pathways. An increased knowledge about the 
interaction between epigenetic modifiers on nuclear kinetics will be important for therapy 
applications using epigenetic drugs. Our study thus sheds light on the molecular mechanisms 
underlying the synergistic action of HDACi and DNMTi and may also provide a basis for 
defining improved policies for cancer treatment using combined epigenetic therapy. 
3.2 STUDY II 
Human cytomegalovirus infection is sensitive to the host cell DNA methylation state and 
alters global DNA methylation capacity 
- Background 
Human Cytomegalovirus (HCMV) is a ubiquitous herpesvirus that infects and establishes 
latency in the majority of the human population, and may cause fatal infections in 
immunocompromised patients. Recent data showed a close interaction between HCMV 
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encoded proteins and cellular epigenetic mechanisms such as histone acetylation and 
deacetylation. An important strategy for viruses should be to change host cell epigenetic 
regulatory systems in favour of the viral functions. This strategy would provide the 
opportunity for the virus to impair host cell protective mechanisms and consequently 
replicate its genome and spread.  
In this study, we examined interactions between HCMV infection and DNA methylation 
machinery in different host cells. 
- Results and discussion 
Our data demonstrated that: 
1- DNA methylation influences cellular susceptibility to HCMV infection.  
2- Human cytomegalovirus inhibits the host cell DNA methylation machinery. 
3- Infection of human fibroblasts by HCMV results in re-localization of DNMTs 
from the nucleus to cytoplasm of the cell. 
In conclusion, HCMV infection results in profound effects on the host cell DNA methylation 
machinery and is associated with inflammation in vivo. Our results improved the 
understanding of cytomegalovirus pathogenesis and may disclose new targets for antiviral 
therapy. These findings may also contribute to the further understanding of mechanisms 
involved in DNA methylation abnormalities in physiological and pathological conditions. 
3.3 STUDY III 
Increased cytomegalovirus replication by 5-Azacytidine and viral-induced cytoplasmic 
expression of DNMT1 in medulloblastoma and endothelial cells 
- Background 
Medulloblastomas (MBs) are the most common pediatric brain tumors and associated with a 
poor prognosis. The etiology of MB is not fully understood, yet the impact of epigenetic 
alterations of oncogenes has previously been established. During the past decade, the human 
cytomegalovirus (HCMV) has been detected in several types of cancer, including MB. Since 
DNA methylation occurs in the cell nucleus and this is, besides being intimately involved in 
gene regulation, also considered a host defense response against invading nucleic acids, we 
studied the impact of HCMV infection on DNA methyltransferase (DNMT1) in MB (D324) 
cells, human umbilical vein endothelial cells (HUVECs) as well as in MB tissue sections. We 
hypothesized that infection and DNMT1 intracellular localization are linked.  
- Results and discussion 
Our results determined that DNMT1 localized to the nucleus of uninfected and HCMV-IE 
expressing D324 cells and HUVECs, but accumulated in the extra nuclear space in all 
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HCMV-gB positive cells. Inhibition of HCMV late protein expression by Cymevene® 
(ganciclovir) prevented the cytoplasmic localization of DNMT1. Treatment of HCMV 
infected D324 cells and HUVECs with the methylation inhibitor 5AZA, significantly 
increased HCMV-IE and late HCMV-gB gene transcription and protein expression. 
Immunohistochemical staining of DNMT1 and HCMV proteins in MB cancer tissue sections 
revealed both nuclear and cytoplasmic DNMT1 localization. In conclusion, DNMT1 resides 
in the cytoplasm of HCMV-gB expressing HUVECs and D324 cells. Increased viral protein 
synthesis in 5AZA treated cells suggests that HCMV replication may benefit from a DNA 
methyltransferase-free cellular environment. Our findings emphasize the importance of 
assessing potential viral activation in the treatment of MB patients with epigenetic drugs. 
3.4 STUDY IV 
Nuclear exclusion of DNA methyltransferase-1, and reduced invasion by 5-azacytidine, 
in human cytomegalovirus infected glioblastoma cells 
- Background 
Glioblastoma (GBM) is the most aggressive brain tumor in the adult, with a devastating 
outcome. Despite aggressive surgery and advanced therapy, the median overall survival of 
these patients is only approximately 14 months. The risk factors for GBM are not well 
understood. Emerging reports support the presence of HCMV proteins and nucleic acids in 
GBM tissues. Furthermore, accumulating data strongly support an association between 
histone modification, chromatin modulation, HCMV genome transcription and replication, 
both at latency and during lytic infection. DNA methylation is important for initiation and 
progression of cancer and is an established host response against invading nucleic acids such 
as viruses. We have previously reported increased HCMV replication in DNA methylation 
inhibited non-tumor (HUVEC) and medulloblastoma cells. 
In this study, we investigated the viral replication, proliferation and invasion capacity of 
5AZA treated HCMV infected GBM cells (U343) and examined the expression of DNMT1 
and HCMV proteins in GBM tissue specimens. 
- Results and discussion 
We observed DNMT1 to be localized in the nucleus of cells expressing HCMV-IE but 
coincided with an extra-nuclear/cytoplasmic localization in U343 cells expressing the 
HCMV-gB protein. In tissue specimens, DNMT1 was expressed in the nucleus of tumor 
cells, but localized to the extra-nuclear/cytoplasmic space of cells lining blood vessel walls 
within the GBM tumors. 5AZA treatment of HCMV infected U343 cells did not affect viral 
replication but attenuated the invasion and proliferation ability of these cells. While 5AZA 
treatment of uninfected U343 cells did not affect invasion ability, proliferation was 
significantly reduced.  
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DNMT1 is localized to the extra nuclear space of U343 cells expressing HCMV-gB proteins 
and in the cells of blood vessel wall within GBM tumors. 5AZA treatment of U343 cells 
leads to reduced proliferation of uninfected and HCMV infected cells while HCMV infected 
cells are vulnerable to 5AZA treatment, leading to a decreased invasion. 
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